Where smart money is flowing in Digital Health
This article originally appeared in the State of Australian Startup Funding 2025 report.
The landscape of Australian healthcare technology has undergone a radical transformation. Gone are the days when the sector was defined by "Health IT," clunky back-end software and basic step-tracking apps. In 2025, digital health has simply become "health," maturing into a high-conviction sector defined by capital discipline, clinical credibility, and major global attention.
A shift in funding dynamics
The current funding environment is characterized by conviction over volume. We are seeing a "barbell-shaped" market: significant large-scale acquisitions and rounds at the top, a long tail of deals under $2 million at the early stage, and very little activity in the middle where traction and regulation are tested.
Key trends driving this shift include:
The return of global and mega-deals: Major foreign VCs and massive acquisitions are redefining the ceiling for Australian health tech. Notable 2025 activity includes Eucalyptus being acquired by Hims & Hers Health for $1.6 billion, HotDoc securing a $250 million investment from Potentia Capital, Saluda Medical pursuing a $231 million ASX Listing, and Point72 leading a $98 million Series B for Heidi Health.
The rise of AI-native health: Investors are moving away from "AI as a slogan" and toward companies where AI is foundational to solving clinical or operational bottlenecks. Standouts include Heidi Health for workflow automation, Nutromics for advanced diagnostics, Sahha.ai for data infrastructure, and OneMRI for precision imaging.
Government and translational support: Programs like the Medical Research Future Fund (MRFF), Breakthrough Victoria, and the Industry Growth Program are cornerstones for early-stage momentum. These are critical for teams proving feasibility, such as Clean Slate Clinic and Laronix.
Strategic consolidation: M&A activity is rising as the sector moves out of adolescence. Recent transactions include Teladoc Health’s acquisition of Telecare, Magentus acquiring Labflow, and Jonas Software’s purchase of MedAdvisor’s ANZ business.
What investors are looking for
The selective lens of 2025 means investors are prioritizing clarity and proof over the narrative-heavy enthusiasm of previous years. Today’s winners demonstrate:
Clinical adjacency: Products that measurably reduce waste or shorten workflows outperform generic wellness tools.
Evidence over narrative: Even early-stage directional data is now a requirement, and long sales cycles must be addressed directly.
Global pathways: The most successful companies, like Everlab and Andromeda, show relevance beyond Australia from day one.
Capital efficiency: Australian founders are increasingly recognized for their ability to do more with less, which is a key reason global funds are returning.
Roadmap for founders in 2026
For founders looking to navigate this landscape in the coming year, the focus should be on practical milestones:
Align with capital movement: Focus on AI-native tools, diagnostics, and virtual care infrastructure.
Prioritise unit economics: Build these early, even if the scale is initially small.
Engage clinical partners: Bring healthcare professionals into the process before investors even ask for them.
Think globally: Frame your market narrative around global demand rather than limiting it to Australian borders.
Australian digital health is no longer a niche. It has become a high-conviction, globally relevant investment category, and the record-breaking capital flows of 2025 finally reflect that reality.
